SB659032

A 24-week Study to Evaluate the Effect of Rilapladib on Cognition and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Authors: Gareth Maher-Edwards, Jeni De'Ath, Carly Barnett, Arseniy Lavrov, Andrew Lockhart

Journal: Alzheimer's & Dementia

Year Published: 2015

Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s disease (AD). Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging […]

Back to Publications